Who Pays My Doctor?

Healthcare provider profile · identity verified

Niku Singh, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · FALLS CHURCH, VA · NPI 1558374595

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Niku Singh, MD received $608,084.00 in general payments during 2025 across 701 reported records.

ABBVIE INC. accounted for 27.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 13 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Trintellix.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$608,084.00

701 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $167,534.2427.6%1592025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $139,938.6723.0%1632025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $133,681.1422.0%1442025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $115,470.0819.0%1132025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $42,585.947.0%522025
Alkermes, Inc. Unresolved — no canonical attribution shown $7,697.381.3%202025
Collegium Pharmaceutical, Inc. Unresolved — no canonical attribution shown $678.480.1%302025
Lundbeck LLC Unresolved — no canonical attribution shown $257.730.0%82025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $185.530.0%102025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $54.810.0%22025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$331,017.00119
Travel and Lodging$124,049.26277
Honoraria$109,275.0038
Consulting Fee$30,070.0012
Food and Beverage$13,649.00253
Education$23.742

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $166,904.77 155 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $139,938.67 163 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $133,681.14 144 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $113,630.08 112 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $42,843.67 60 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $7,697.38 20 2025
Source payment records
Jornay PM
Normalized: jornay pm		 Drug Collegium Pharmaceutical, Inc. $678.48 30 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $185.53 10 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $167.63 5 2025
Source payment records
QULIPTA
Normalized: qulipta		 Drug ABBVIE INC. $79.47 3 2025
Source payment records
TRINTELLIX
Normalized: trintellix		 Drug Takeda Pharmaceuticals U.S.A., Inc. $54.81 2 2025
Source payment records
HETLIOZ
Normalized: hetlioz		 Drug Vanda Pharmaceuticals Inc. $35.67 6 2025
Source payment records
UBRELVY
Normalized: ubrelvy		 Drug ABBVIE INC. $17.67 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
TRINTELLIX
trintellix		 2025 Trintellix 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Takeda Pharmaceuticals U.S.A., Inc.
Exact reporting entity; no affiliate inference		 2025 TRINTELLIX
open payments reported associated product		 CMS Open Payments — General Payments
37075 supporting records · 14402 recipient NPIs · example record 1223616266 		Trintellix · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Quetiapine FumarateQuetiapine Fumarate6415
Duloxetine HclDuloxetine Hcl4713
ClonazepamClonazepam33suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29suppressed
AripiprazoleAripiprazole26suppressed
Trazodone HclTrazodone Hcl2611
Bupropion XlBupropion Hcl25suppressed
BelsomraSuvorexant20suppressed
GabapentinGabapentin17suppressed
Escitalopram OxalateEscitalopram Oxalate15suppressed
LorazepamLorazepam15suppressed
Venlafaxine Hcl ErVenlafaxine Hcl14suppressed
LamotrigineLamotrigine13suppressed
MounjaroTirzepatide13suppressed
AlprazolamAlprazolam12suppressed
ClozapineClozapine12suppressed
OlanzapineOlanzapine11suppressed
TrintellixVortioxetine Hydrobromide11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $608,084.00 · 701 records ABBVIE INC. ARISTADA, Auvelity, CAPLYTA, COBENFY, FANAPT, HETLIOZ, Jornay PM, LYBALVI, QULIPTA, REXULTI, TRINTELLIX, UBRELVY, VRAYLAR 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error